pharma · MANKIND
Mankind Pharma
Mankind Pharma: PE below historical average. ROTATIONAL regime.
Price
₹2,385
Price 2026-08-20
5 day
-1.66%
Short-term move
1 month
-7.54%
Medium-term
Regime
ROTATIONAL
68% confidence
Market cap
₹104.4k Cr
neutral sector flow
Market Intelligence Analyst
Understand today's market in about 2 minutes.
“How does today's ROTATIONAL regime affect Mankind Pharma (MANKIND) in the pharma sector?”
Price chart
₹2,380
-10.23% over period
About Mankind Pharma
Mankind Pharma Limited develops, manufactures, and markets pharmaceutical formulations and consumer healthcare products in India and internationally. The company develops pharmaceuticals for acute and chronic therapeutics in the areas of anti-infective, cardiovascular, gastrointestinal, gynaecology, urology, anti-diabetic, dermatology, pain/analgesics, neuro/CNS, vitamins/minerals/nutrients, respiratory, and other diseases. It also provides consumer healthcare products, such as condoms, pregnancy detection, emergency contraceptives, antacid powders, vitamin and mineral supplements, and anti-acne preparations. In addition, the company engages in the trading of pharmaceutical and health care products; manufacture of packing materials, ayurvedic products, and consumer goods; real estate, leasing, and hospitality businesses; trading of agricultural and pet food products; and provision of IT services. It offers its products under the Manforce, Moxi Kind-Cv, AmLokind-At, Unwanted-Kit, Prega News, Dydroboon, Telmikind-Am, Gudcef, Glimestar-M, Candi Force, Nurokind-Gold, Telmikind-H, Telmikind, Nurokind-Lc, Nurokind Plus-Rf, Vomikind, Cefakind, Glizid-M, Monticope, and Gudcef-Cv brand n...
At a Glance
RSI pattern warning
RSI oversold bounces for this stock succeeded only 0% of the time (avg -7.1% over 14 days) — not a reliable pattern.
52-week position
Trading at 87.8% of 52-week high
Technicals
RSI 14
34.3
Trend
mixed
50 DMA
Below
200 DMA
Above
Key metrics
P/E ratio
54.6
29th pct · 7 quarterly points (limited history)
P/B
6.4
ROE
12.4%
Moderate profitability — 12.4% ROE
Market cap
₹104.4k Cr
Revenue growth
1180.0% YoY
Promoter
75.4%
52-week range
₹1,909.7 – ₹2,716.5
87.8% of high
RSI (14)
34.3
mixed
vs 50 DMA
Below
DMA ₹2,480.07
Coverage
100/100
HIGH
Quick Take
Mankind Pharma: PE below historical average. ROTATIONAL regime.
Peer comparison
| Stock | Price | 5D | P/E | ROE | Rev growth | Mcap |
|---|---|---|---|---|---|---|
| DIVISLAB Divi's Laboratories | ₹8,570 | +0.8% | 70 | 16.2% | 950% | ₹1.8L Cr |
| CIPLA Cipla | ₹1,438 | -1.4% | 30.2 | 11.7% | -210% | ₹1.2L Cr |
| DRREDDY Dr. Reddy's Laboratories | ₹1,180 | -2.2% | 26.5 | 11.8% | -1160% | ₹1.1L Cr |
| AUROPHARMA Aurobindo Pharma | ₹1,608 | -3.3% | 26.3 | 9.9% | 560% | ₹91.1k Cr |
| ALKEM Alkem Laboratories | ₹5,400 | -0.9% | 29.4 | 17.6% | 1460% | ₹67.8k Cr |
| BIOCON Biocon | ₹412.5 | -1.8% | 145.3 | 1.1% | 230% | ₹66.3k Cr |
| GLENMARK Glenmark Pharmaceuticals | ₹2,332.9 | +0.6% | 47 | 14.1% | 1430% | ₹63.9k Cr |
| GLAND Gland Pharma | ₹2,820 | -5.0% | 40.9 | 10.5% | 2230% | ₹42.1k Cr |
| MANKIND Mankind Pharma | ₹2,385 | -0.8% | 54.6 | 12.4% | 1180% | ₹1.0L Cr |
Tensions to watch
PE in bottom 29% historically — undervaluation or fundamental deterioration?
Low PE can signal value OR declining growth expectations. Check recent earnings and sector outlook.
Key Watchpoints
Breaks above ₹2504 (+5%)
Trend reversal confirmation
Breaks below ₹2266 (-5%)
Further downside risk
PE reverts to median of 54.7 (7 quarterly points (limited history))
Valuation normalization
Pharma sector entering leadership
Sector rotation signal
